Peginterferon alfa-2a
- Generic Name
- Peginterferon alfa-2a
- Brand Names
- Pegasys
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 198153-51-4
- Unique Ingredient Identifier
- Q46947FE7K
- Background
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, HBeAg Positive Chronic Hepatitis B
- Associated Therapies
- -
Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 253
- Registration Number
- NCT02822547
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 81
- Registration Number
- NCT02806505
A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT02791269
A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6
- Conditions
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT02791256
HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients
- Conditions
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- José Antonio Carrion
- Target Recruit Count
- 119
- Registration Number
- NCT02743182
Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT02736721
A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)
- Conditions
- Interventions
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02731131
A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT02726022
SR-BI and Antiviral Treatment Response in HCV
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2017-07-14
- Target Recruit Count
- 309
- Registration Number
- NCT02714712
A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)
- Conditions
- Interventions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 737
- Registration Number
- NCT02641379
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.